Alex Vasaly consults on financial and economic issues in complex commercial litigation and regulatory proceedings. Mr. Vasaly focuses on matters involving securities litigation, valuation, and mergers and acquisitions. He supports experts and attorneys through all phases of litigation, including deposition, mediation, and trial.
Mr. Vasaly analyzes damages, market efficiency, price impact, and loss causation in Rule 10b-5 and Section 11 cases. He has worked on matters involving common stock and bonds issued by firms in a range of industries, notably banking, healthcare, pharmaceuticals, and real estate. His experience also includes issues related to financial accounting restatements, government investigations, risk management, business combinations, and the clinical development of pharmaceutical drugs.
Mr. Vasaly values companies in appraisal proceedings and commercial disputes in federal and state courts, as well as in international jurisdictions. He has extensive experience applying discounted cash flow (DCF), comparable company, and precedent transaction valuation methodologies, and determining appropriate costs of capital. Mr. Vasaly has also addressed issues related to market efficiency and deal process in connection with acquisitions of public companies.
Merger efficiencies and investigations
Mr. Vasaly consults on horizontal and vertical merger reviews on behalf of both merging parties and government agencies. He has assessed merger-specificity and verifiability of claimed efficiencies in numerous matters, including U.S. v. Aetna/Humana. Mr. Vasaly has also analyzed the competitive effects and valuation impacts of proposed and completed mergers.
Prior to joining Cornerstone Research, Mr. Vasaly worked in real estate finance at JPMorgan.
Cornerstone Research Staff and Affiliated Experts Submit Comments to the Joint FTC-DOJ Inquiry on Merger Enforcement
Cigna’s Acquisition of Express Scripts
Proposed Merger of Aetna and Humana Enjoined